<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414947</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2111</org_study_id>
    <nct_id>NCT00414947</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers</brief_title>
  <official_title>A Single Center, Randomized, Open-Label, Crossover, Single Oral Dose Study to Assess the Bioequivalence of LAF237 Tablet Manufactured by Beijing Novartis Pharma Ltd. to Imported LAF237 Tablet in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the bioequivalence as well as rate and extent of absorption of
      vildagliptin tablet manufactured by Beijing Novartis Pharma Ltd. compared to the imported
      vildagliptin tablet in Chinese healthy volunteers.

      This trial is not recruiting patients in the United States,
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and extent of absorption of vildagliptin tablet manufactured by Beijing Novartis Pharma Ltd. to imported vildagliptin tablet in Chinese healthy subjects</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of vildagliptin tablet after a 50 mg single dose</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin (LAF237)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese healthy male subjects age 18 to 40 years of age included

          -  In good health

          -  Male subjects using a double-barrier local contraception for the entire duration of
             the study up to study completion visit and refraining from fathering a child in the
             three months following last study drug administration.

          -  Body mass index within the range of 19 to 24 kg/m2 and weigh at least 50 kg

        Exclusion Criteria:

          -  Smokers

          -  Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter
             medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to
             dosing. Paracetamol is acceptable.

          -  Participation in any clinical investigation within 4 weeks prior to dosing.

          -  Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or
             longer if required by local regulation.

          -  Significant illness within two weeks prior to dosing.

          -  A past personal or close family medical history of clinically significant cardiac
             abnormalities.

          -  History of:

               -  Fainting, low blood pressure when standing, irregular heartbeats,

               -  Acute or chronic bronchospastic disease (including asthma and chronic obstructive
                  pulmonary disease, treated or not treated),

               -  Clinically significant drug allergy or history of atopic allergy (asthma,
                  urticaria, eczematous dermatitis)

               -  Known hypersensitivity to the study drug or similar drugs

               -  Any surgical or medical condition which might significantly alter the absorption,
                  distribution, metabolism or excretion of drugs or jeopardize participation in the
                  study.

               -  Immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test
                  result.

          -  Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

          -  Drug or alcohol abuse within the 12 months prior to dosing

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>safety</keyword>
  <keyword>LAF237</keyword>
  <keyword>vildagliptin</keyword>
  <keyword>Chinese</keyword>
  <keyword>healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

